Press Releases Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
30.64 ^USD	-5.72%		-6.61%	+58.10%

10/05	Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
07/05	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	13/05	AQ
Neurogene: Q1 Earnings Snapshot	10/05	AQ
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	10/05	BU
Neurogene : ASGCT NGN-401 Clinical Safety Poster	07/05	PU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting	07/05	BU
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	23/04	BU
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	19/03	BU
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03	BU
Neurogene to Participate in Upcoming Investor Conferences	29/02	BU
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01	BU
Neurogene Announces Business Update and 2024 Outlook	05/01	BU
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million	20/12	AQ
Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K	19/12	PU
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split	15/12	AQ
Neoleukin: Q3 Earnings Snapshot	14/11	AQ
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split	22/23/22	GL
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split	22/23/22	AQ
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX	25/23/25	BU
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene	18/23/18	PR
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders	18/23/18	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Neurogene Inc.

Equities

NGNE

US64135M1053

Press Releases

Filters